Diasome Pharmaceuticals
PrivateLast Round
Series C
Dec 7, 2023
Est. Valuation
$86M
Total Funding Raised
$51.14M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Diasome Pharmaceuticals operates in Healthcare & Life Sciences and is based in Cleveland, Ohio. Its latest recorded funding round was a Series C round in December 2023.
Diasome Pharmaceuticals is a biotechnology company that develops innovative, cell-targeted therapies aimed at treating diabetes, obesity, and other metabolic disorders through proprietary liver-targeted insulins that help manage blood sugar levels effectively.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diasome Pharmaceuticals Comparables
Compare Diasome Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adocia | 75% | |
| vTv Therapeutics Inc | 73% | |
| Oramed Pharmaceuticals Inc. | 73% |
For institutional investors. Book with your work email.
Diasome Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 7, 2023 | ||||
| VC Round | Sep 22, 2022 | ||||
| Series B | Aug 26, 2022 | ||||
| Series B | Dec 23, 2020 | ||||
| Series A | Jul 5, 2017 | ||||
Debt | Dec 16, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Diasome Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Quaker Partners | Series B |
| Quaker Partners Management | Series B |
| Devon Park BioVentures | Series B |
| Black Beret Life Sciences | Series A |
| JDRF | Series A |
| BioAdvance Capital | Series B |
| Medicxi | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 62% MoM.
- Aug 20, 2026
Monthly visitors grew 1394% MoM, reaching 2.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 21, 2026
Diasome plans to present HDV-Insulin Phase 2b clinical data at EASD 2026 in Italy from Sep 28th to Oct 2nd '26 and at the inaugural Breakthrough T1D Clinical & Research Congress in Pennsylvania from Oct 9th to 11th '26, highlighting OPTI-2 findings and new exposure-adjusted incidence rate analyses.
- attends_eventSep 21, 2026
Diasome plans to present HDV-Insulin Phase 2b clinical data and new exposure-adjusted incidence rate analyses at the Breakthrough T1D Clinical & Research Congress in Pennsylvania in Oct '26.
- attends_eventSep 21, 2026
Diasome announces upcoming scientific presentations at the 62nd Annual Meeting of EASD in Italy from Sep 28th-Oct 2nd '26, featuring findings from its Phase 2b OPTI-2 study.
- hiresSep 15, 2026
Diasome appoints Sangeeta Sawhney as Chief Medical Officer to lead clinical development as it advances HDV-Insulin toward Phase 3 development in Ohio and Massachusetts on Sep 15th '26.
For institutional investors. Book with your work email.
Diasome Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Diasome Pharmaceuticals's valuation, stock price, and market status.
Is Diasome Pharmaceuticals a public or private company?
Diasome Pharmaceuticals is a private company.
What is the current stock price of Diasome Pharmaceuticals?
Diasome Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Diasome Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Diasome Pharmaceuticals worth (valuation)?
Diasome Pharmaceuticals's valuation is estimated at $86.0M based on funding round data.
Can I buy Diasome Pharmaceuticals stock?
Diasome Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Diasome Pharmaceuticals's last funding round?
Diasome Pharmaceuticals's most recent funding round was Series C on December 7, 2023.
Who are the main investors in Diasome Pharmaceuticals?
Key investors in Diasome Pharmaceuticals include Quaker Partners, Quaker Partners Management, Devon Park BioVentures, Medicxi.
Will Diasome Pharmaceuticals IPO soon?
No public IPO plans have been announced for Diasome Pharmaceuticals.
How can I track Diasome Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Diasome Pharmaceuticals's shares on secondary markets.